$17m funding for Click Therapeutics

Click Therapeutics, Inc. is developing prescription digital therapeutics for the treatment of depression (CT-152), insomnia (CT-141), acute coronary syndrome (CT-111), and chronic pain (CT-130). They have recently received $17m funding led by Sanofi Venures with help them to maintain and grown this pipeline.
Bernard Davitian, SVP and MD of Sanofi Ventures, said: “We’ve evaluated many companies in this space, and we believe Click Therapeutics’ mobile patient engagement platform positions the company to be a leader in the field of prescription digital therapeutics. Click’s platform enables the company to target multiple indications efficiently and effectively, and we have invested with the intent of partnering across a variety of therapeutic areas. Sanofi Ventures is excited to join Click on this journey of building a new pillar of medicine.”
Co-founder and CEO of Click, David Benshoof Klein, said: “The Click Therapeutics team is proud to partner with Sanofi Ventures to advance our pipeline and expand our product portfolio of prescription medical treatments. As we announced last summer, in 2017 we expanded our collaboration with Magellan Health, Inc. to pursue regulatory clearance from the FDA for indication-specific prescription digital therapies, leveraging the industry-leading suite of intellectual property and data from Magellan’s existing software as well as their vast coverage and reimbursement leadership. The addition of Sanofi as a strategic investor, and the closing of this financing, represent major steps forward for Click and for the field of software as prescription medical treatments. By connecting patients with cognitive and neurobehavioral interventions, our platform will bring clinically-validated digital therapeutic solutions into mainstream healthcare.”